First report of CTX-M-15 and CTX-M-3 beta-lactamases among clinical isolates of Enterobacteriaceae in Béjaia, Algeria

International Journal of Antimicrobial Agents
Abdelaziz TouatiChristophe De Champs

Abstract

We assessed the prevalence and phenotypic characteristics of extended-spectrum beta-lactamase producers among 365 clinical isolates of members of the family Enterobacteriaceae recovered from two hospitals in Béjaia, Algeria, between March 2004 and April 2005. Twenty-one strains were resistant to cefotaxime and/or ceftazidime. A double-disk synergy test yielded a positive result in five cases (three Escherichia coli, one Klebsiella pneumoniae and one Enterobacter cloacae). Using polymerase chain reaction and sequencing, the three E. coli isolates and the K. pneumoniae isolate were found to produce extended-spectrum beta-lactamase CTX-M-15 and the E. cloacae isolate produced CTX-M-3. The three CTX-M-15-producing E. coli isolates were not isolated in the same wards, although genotyping by randomly amplified polymorphic DNA analysis revealed that they were clonally related. The bla(CTX-M-15) genes were transferred from E. coli by conjugation, whilst conjugative transfer of bla(CTX-M) genes from K. pneumoniae and E. cloacae was not detectable.

References

Sep 1, 1990·Infection·A BauernfeindS Schweighart
Jun 1, 1995·Antimicrobial Agents and Chemotherapy·K BushA A Medeiros
Apr 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P L WinokurN Legakis
Jan 18, 2002·Antimicrobial Agents and Chemotherapy·C DutourJ Sirot
Aug 17, 2002·Antimicrobial Agents and Chemotherapy·Christel HumeniukAlain Philippon
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Laurent PoirelPatrice Nordmann
Mar 30, 2004·Antimicrobial Agents and Chemotherapy·Michael R MulveyUNKNOWN Canadian Hospital Epidemiology Committee, Canadian Nosocomial Infection Surveillance Program, Health Canada
Aug 11, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R MarkovskaA Bauernfeind
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·J Gangoue-PiebojiL S Tzouvelekis
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·T ConceiçãoM J Salgado
May 27, 2005·The Journal of Antimicrobial Chemotherapy·Johann D D PitoutLaurent Poirel
Feb 24, 2006·Antimicrobial Agents and Chemotherapy·Janusz FiettMarek Gniadkowski

❮ Previous
Next ❯

Citations

Aug 14, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C M LonchelP De Mol
Jul 19, 2012·World Journal of Microbiology & Biotechnology·Adel AouicheAhmed Lebrihi
Jul 27, 2007·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Abdelaziz TouatiChristophe De Champs
May 21, 2008·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Rumyana MarkovskaAdolf Bauernfeind
Dec 7, 2010·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Nevine FamMarie-Hélène Nicolas-Chanoine
Aug 10, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Samia HammamiSaida Ben Redjeb
Jan 11, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Zaket Baba Ahmed-Kazi TaniMourad Drissi
Jan 15, 2010·Annals of Clinical Microbiology and Antimicrobials·Shazi Shakil, Asad U Khan
Aug 21, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Souhila AlouacheRabah Bakour
May 14, 2014·Pathologie-biologie·Z Baba Ahmed-Kazi Tani, G Arlet
Feb 21, 2007·Journal of Chemotherapy·M TonkicV Punda-Polic
Aug 14, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J PépinL Valiquette
Aug 15, 2017·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Soumia BrahmiJean-Philippe Lavigne
Jan 25, 2019·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Larbi Zakaria NabtiSylvain Godreuil
Nov 21, 2009·Journal of Clinical Laboratory Analysis·Zhijian ZhangQinxian Zhang
Oct 12, 2019·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Ferielle Mesbah ZekarYves Millemann
Oct 24, 2019·Veterinary World·Djanette BarourNadji Boulebda
Dec 11, 2021·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Djahida SounaMax Maurin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.